Stand strong and vote NO!, page-89

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 89 Last

Share
Profile

Follow
ravanelli77

2,885 Posts.

285

06/08/22

01:51

Post #: 62957970
Share

Originally posted by maria1240: ↑

@ccforum for a 6 years long term holder, it seems extremely odd that you only have 7 posts. You must be busy with other stocks.

Many holders will agree with you and also this has been discussed as well that if Pfizer walks, we will need a CR. That is inevitable. However, at what price? This depends on the offer from Pfizer. If the price is 14.6c when Pfizer walks, we might have to raise at 5c. However, the higher the offer is, the better price we can have. How much Pfizer is willing to offer? I don't know but it does not look like it can take our company for 20.8c. If it goes higher, say 28c which is the high end of the IER, we will then be able to have a CR at 10c which does not look so bad then. Our company has only done 5 CR so far and has NEVER tapped retail share holders. We now have one FDA, I am very confident that many retail holders would like to participate. I for one, will and I have told the computershare operators multiple times. But will it be with current BOD? I don't know. If the BOD can't act for our interest, then why bother?

Pfizer made a big mistake by offering 11.5c and then many new posters here tried to scare people by saying if Pfizer walks, we will go down to 4c. Why? because so many holders are in deep red with 11.5c, especially all the investors who participated in the last CR at 22.5c. Then they lifted to 14.6c and 20.8c. Now comes the trouble for Pfizer. I said in other posts before, the more times Pfizer increases, the less scared share holders are and more will vote for no. Because people actually realize that Pfizer does want our company and will not go away. second, it makes our CR price higher, should Pfizer walk. Therefore, holders are more firm with voting NO.

Pfizer needs to close this deal soon as they must work with us to get FDA approval BEFORE winter hits USA and CHINA. In winter, there will be a big surge of COVID numbers in USA and also CHINA too. Pfizer does NOT want to miss the opportunity. Hence the so called R&D finishes in October which will give Pfizer 1-2 months to get FDA and then make great profit from it.

Let us hold tight and vote no. Good things will happen. Of course, it is IMHO, do your own research.

Expand

I cant understand why Pfizer cant offer lets say 2 AUD from the beginning. Would be such a premium that probably everybody would sell. The weak shareholder register is the big chance to pinch money from Pfizer. In a good way. IMO

Not saying yes or no. Just that if Tech really works, their is no price which is fair value

and if Pfizer quits and sp react negatively I would buy hard. (No advice just my opinion)

IMO and perception

RAP Price at posting: 19.0¢ Sentiment: Buy Disclosure: Held
11 Upvote

1 Great analysis

Reply

Top Stories

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

VUL

Vulcan appoints investment bank and M&A veteran to board

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

There are more pages in this discussion • 32 more messages in this thread...

First 89 Last

Add RAP (ASX) to my watchlist

Stand strong and vote NO!, page-89

Top Stories

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Utah authorities sign off on Anson's lithium extraction plans at Green River

Vulcan appoints investment bank and M&A veteran to board

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Featured News